Fernandez-Checa et al., ADVANCED PRECLINICAL MODELS FOR EVALUATION OF DRUG INDUCED LIVER INJURY - CONSENSUS STATEMENT BY THE EUROPEAN DRUG-INDUCED LIVER INJURY NETWORK [PRO-EURO-DILI-NET] J Hepatol. 2021; S0168-8278(21)00441-4. doi: 10.1016/j.jhep.2021.06.021 (open access)
Esteves F, Rueff J, Kranendonk M. The Central Role of Cytochrome P450 in Xenobiotic Metabolism-A Brief Review on a Fascinating Enzyme Family. J. Xenobiot. 2021; 11(3):94-114. doi: 10.3390/jox11030007 (open access)
Silveira, C.M., Rodrigues, P.R., Ghach, W., Pereira, S.A., Esteves, F., Kranendonk, M., Etienne, M., Almeida, M.G. Electrochemical Activity of Cytochrome P450 1A2: The Relevance of O2 Control and the Natural Electron Donor ChemElectroChem 2021, 8, 500–507. doi: 10.1002/celc.202001255
Esteves F, Urban P, Rueff J, Truan G, Kranendonk M. Interaction Modes of Microsomal Cytochrome P450s with Its Reductase and the Role of Substrate Binding. Int. J. Mol. Sci. 2020; 21(18):6669. doi: 10.3390/ijms21186669 (open access)
Esteves F, Campelo D, Gomes BC, Urban P, Bozonnet S, Lautier T, Rueff J, Truan G, Kranendonk M. The Role of the FMN-Domain of Human Cytochrome P450 Oxidoreductase in Its Promiscuous Interactions with Structurally Diverse Redox Partners. Frontiers Pharmacol. 2020; 299. doi: 10.3389/fphar.2020.00299 (open access)
Rueff J, Rodrigues AS, Kranendonk M. A personally guided tour on some of our data with the Ames assay-A tribute to Professor Bruce Ames. Mutat. Res. 2019 Oct;846:503094. doi: 10.1016/j.mrgentox.2019.503094.
Quast RB, Fatemi F, Kranendonk M, Margeat E, Truan G. Accurate Determination of Human CPR Conformational Equilibrium by smFRET Using Dual Orthogonal Noncanonical Amino Acid Labeling. Chembiochem. 2019;20(5):659-666. doi: 10.1002/cbic.201800607.
Esteves F, Campelo D, Urban P, Bozonnet S, Lautier T, Rueff J, Truan G, Kranendonk M. Human cytochrome P450 expression in bacteria: Whole-cell high-throughput activity assay for CYP1A2, 2A6 and 3A4. Biochem. Pharmacol. 2018, 158: 134-140. doi: 10.1016/j.bcp.2018.10.006
Amit V. Pandey, Colin J. Henderson, Yuji Ishii, Michel Kranendonk, Wayne L. Backes, Ulrich M. Zanger, Role of Protein-Protein Interactions in Metabolism: Genetics, Structure, Function. Frontiers Research Topic ebook published in: Frontiers in Pharmacology (2018), by Frontiers Media SA (https://www.frontiersin.org/research-topics/4658/role-of-protein-protein-interactions-in-metabolism-genetics-structure-function) (open access)
Campelo D, Esteves F, Brito Palma B, Costa Gomes B, Rueff J, Lautier T, Urban P, Truan G, Kranendonk M. Probing the Role of the Hinge Segment of Cytochrome P450 Oxidoreductase in the Interaction with Cytochrome P450. Int. J. Mol. Sci. 2018; 19(12):3914. doi: 10.3390/ijms19123914 (open access)
Campelo D, Lautier T, Urban P, Esteves F, Bozonnet S, Truan G, Kranendonk M. The Hinge Segment of Human NADPH-Cytochrome P450 Reductase in Conformational Switching: The Critical Role of Ionic Strength. Frontiers Pharmacol. 2017; 8:755. doi: 10.3389/fphar.2017.00755 (open access)
McCammon KM, Panda SP, Xia C, Kim JJ, Moutinho D, Kranendonk M, Auchus RJ, Lafer EM, Ghosh D, Martasek P, Kar R, Masters BS, Roman LJ. Instability of the Human Cytochrome P450 Reductase A287P Variant Is the Major Contributor to Its Antley-Bixler Syndrome-like Phenotype. J. Biol. Chem. 2016;291(39):20487-502. doi: 10.1074/jbc.M116.716019.
Palma BB, Moutinho D, Urban P, Rueff J, Kranendonk M. Cytochrome P450 expression system for high-throughput real-time detection of genotoxicity: Application to the study of human CYP1A2 variants. Mutat Res Genet Toxicol Environ Mutagen. 2016 806:24-33. doi: 10.1016/j.mrgentox.2016.06.004
Palma BB, Fisher CW, Rueff J, Kranendonk M. Prototype Systems Containing Human Cytochrome P450 for High-Throughput Real-Time Detection of DNA Damage by Compounds That Form DNA-Reactive Metabolites. Chem Res Toxicol. 2016; 29(5):747-56. doi: 10.1021/acs.chemrestox.5b00455.
Kranendonk M, Alves M, Antunes P, Rueff J. Human sulfotransferase 1A1-dependent mutagenicity of 12-hydroxy-nevirapine: the missing link? Chem Res Toxicol. 2014; 27(11):1967-71. doi: 10.1021/tx5003113.
Palma BB, Silva E Sousa M, Urban P, Rueff J, Kranendonk M. Functional characterization of eight human CYP1A2 variants: the role of cytochrome b5. Pharmacogenet Genomics. 2013; 23(2):41-52. doi: 10.1097/FPC.0b013e32835c2ddf
Moutinho D, Marohnic CC, Panda SP, Rueff J, Masters BS, Kranendonk M. Altered human CYP3A4 activity caused by Antley-Bixler syndrome-related variants of NADPH-cytochrome P450 oxidoreductase measured in a robust in vitro system. Drug Metab. Dispos. 2012;40(4):754-60. doi: 10.1124/dmd.111.042820.
Gómez-Bombarelli R, Palma BB, Martins C, Kranendonk M, Rodrigues AS, Calle E, Rueff J, Casado J Alkylating potential of oxetanes. . Chem Res Toxicol. 2010; 23(7):1275-81. doi: 10.1021/tx100153w
Palma BB, Silva E Sousa M, Vosmeer CR, Lastdrager J, Rueff J, Vermeulen NP, Kranendonk M. Functional characterization of eight human cytochrome P450 1A2 gene variants by recombinant protein expression. Pharmacogenomics J. 2010; 10(6):478-88. doi: 10.1038/tpj.2010.2.
Marohnic CC, Panda SP, McCammon K, Rueff J, Masters BS, Kranendonk M. Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences and rescue of defect. Drug Metab Dispos. 2010; 38(2):332-40. doi: 10.1124/dmd.109.030445.
Kranendonk M, Marohnic CC, Panda SP, Duarte MP, Oliveira JS, Masters BS, Rueff J. Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase. Arch Biochem Biophys. 2008; 475(2):93-9. doi: 10.1016/j.abb.2008.04.014.